Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 and Tarceva in Advanced NSCLC
NCT01487265Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Mar 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buparlisib in non-small cell lung cancer (NSCLC), sponsored by SCRI Development Innovations. Started Mar 2014; status: completed.
02
Drugs
buparlisib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01487265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01487265.